Novo Nordisk A/S Gets Green Light for Tresiba in EU
Published: Jan 22, 2013
The European Commission has issued clearance to market Novo Nordisk's diabetes therapies, Tresiba and Ryzodeg, across 27 European Union (EU) states. Novo Nordisk anticipates launching Tresiba, brand name of insulin degludec, in the UK and Denmark during the first six months of 2013 and in other states all through 2013 and 2014. The company will offer Tresiba in two concentrations with 80 and 160 units per injection doses. Another insulin Ryzodeg, the brand name for insulin degludec/insulin aspart, will be introduced a year after Tresiba launch. Both the products will be made available in FlexTouch prefilled insulin pen. Novo Nordisk executive vice president and chief science officer Mads Krogsgaard Thomsen said the marketing authorizations are the important mile stones for the company and diabetes treatment.